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Abstract
Background: Pluripotent, Lin–/CD45–/Sca-1+ very small embryonic-like stem cells (VSELs) in mouse bone marrow
(BM) are resistant to total body radiation because of their quiescent nature, whereas Lin–/CD45+/Sca-1+ hematopoietic
stem cells (HSCs) get eliminated. In the present study, we provide further evidence for the existence of VSELs in mouse
BM and have also examined the effects of a chemotherapeutic agent (5-fluorouracil (5-FU)) and gonadotropin
hormone (follicle-stimulating hormone (FSH)) on BM stem/progenitor cells.
Methods: VSELs and HSCs were characterized in intact BM. Swiss mice were injected with 5-FU (150 mg/kg) and
sacrificed on 2, 4, and 10 days (D2, D4, and D10) post treatment to examine changes in BM histology and effects on
VSELs and HSCs by a multiparametric approach. The effect of FSH (5 IU) administered 48 h after 5-FU treatment was
also studied. Bromodeoxyuridine (BrdU) incorporation, cell cycle analysis, and colony-forming unit (CFU) assay were
carried out to understand the functional potential of stem/progenitor cells towards regeneration of chemoablated
marrow.
Results: Nuclear OCT-4, SCA-1, and SSEA-1 coexpressing LIN–/CD45– VSELs and slightly larger LIN–/CD45+ HSCs
expressing cytoplasmic OCT-4 were identified and comprised 0.022 ± 0.002 % and 0.081 ± 0.004 % respectively of the
total cells in BM. 5-FU treatment resulted in depletion of cells with a 7-fold reduction by D4 and normal hematopoiesis
was re-established by D10. Nuclear OCT-4 and PCNA-positive VSELs were detected in chemoablated bone sections
near the endosteal region. VSELs remained unaffected by 5-FU on D2 and increased on D4, whereas HSCs showed a
marked reduction in numbers on D2 and later increased along with the corresponding increase in BrdU uptake and
upregulation of specific transcripts (Oct-4A, Oct-4, Sca-1, Nanog, Stella, Fragilis, Pcna). Cells that survived 5-FU formed
colonies in vitro. Both VSELs and HSCs expressed FSH receptors and FSH treatment enhanced hematopoietic recovery
by 72 h.
Conclusion: Both VSELs and HSCs were activated in response to the stress created by 5-FU and FSH enhanced
hematopoietic recovery by at least 72 h in 5-FU-treated mice. VSELs are the most primitive pluripotent stem cells
in BM that self-renew and give rise to HSCs under stress, and HSCs further divide rapidly and differentiate to
maintain homeostasis. The study provides a novel insight into basic hematopoiesis and has clinical relevance.
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Background
In the last decade various groups have reported the pres-
ence of non-hematopoietic stem cells in the bone marrow
(BM) [1–5] using an array of cell surface markers. In
2006, a rare population of these cells expressing pluripo-
tent markers Oct-4 and Nanog was identified and well
characterized in the bone marrow [6]. Over the decade
these LIN–/CD45–/SCA-1+ in mice and CD133+ in
humans, very small embryonic-like stem cells (VSELs)
have been described in various murine and human adult
tissues including bone marrow [7, 8], cord blood [9–11],
testis [12, 13], ovary [14, 15], uterus [16], pancreas [17],
and other organs [18, 19]. True to their pluripotent na-
ture, the human and murine VSELs under specific condi-
tions give rise to cells of all the three germ layers in
vitro [6, 20, 21]. VSELs are quiescent in nature owing
to partial erasure of imprinted genes [22, 23] and thus
do not either expand easily in vitro or form teratoma.
However, several reports have shown that VSELs enter
the cell cycle and mobilize in response to stress or tis-
sue injury [24–30]. In the hematopoietic system, VSELs
are considered to be at the top of the hierarchy, be-
cause the CD45– VSELs in vitro give rise to the CD45+
hematopoietic stem cells (HSCs) [31, 32]. Till date,
however, the role of VSELs in hematopoiesis in vivo ei-
ther in steady-state conditions or in response to bone
marrow injury has not been studied extensively.
Ratajczak’s group [6] was the first to study VSELs
(LIN–/CD45–/SCA-1+) and HSCs (LIN–/CD45+/Sca-1+)
in mouse BM by flow cytometry. The main distinction
between the two cell types is the presence or absence of
CD45 expression. CD45 is pan-hematopoietic marker
which is expressed by all leukocytes, including HSCs
[33]. Others have also reported that cells which express
CD45 and CD34 but lack CD38 and lineage antigens
(CD45+CD34+CD38–Lin–) are HSC populations [34] and
LIN–/CD45–/SCA-1+ are VSELs [20]. Being pluripotent
and not committed to the hematopoietic fate, VSELs do
not express CD45, are negative for LIN markers, and ra-
ther express pluripotent markers. Besides the cell surface
marker profile, VSELs and HSCs are also distinguished
from each other based on their size and OCT-4 expres-
sion pattern. Oct-4 is a nuclear transcription factor cru-
cial to maintain the pluripotent state and its gene is
known to be alternatively spliced and has pseudogenes
[35–38]. OCT-4 isoform 1 (transcript Oct-4A) is local-
ized in the nucleus, maintains stemness properties, and
confers self-renewal function, whereas OCT-4 isoform 2
(transcript Oct-4B) is localized in the cytoplasm and has
no assigned biological function as yet [39]. We have re-
ported VSELs with nuclear OCT-4A and slightly bigger
progenitors with cytoplasmic OCT-4 in adult testis
(spermatogonial stem cells (SSC)) [12], ovary (ovarian
stem cells (OSC)) [14], and Wharton’s jelly (mesenchymal
cells (MSC)) [40] using a polyclonal OCT-4 antibody
which detects both of the isoforms. Based on the OCT-4
staining pattern, we have postulated that immediate de-
scendants or “progenitors” (SSCs, OSCs, MSCs) with
cytoplasmic OCT-4 supposedly arise from the pluripotent
VSELs. Nuclear form of OCT-4A is no longer required
when VSELs initiate differentiation, in the progenitors it is
expressed in the cytoplasm, and eventually get degraded as
cells differentiate further. Besides OCT-4, VSELs also express
several other pluripotent and primordial germ cell markers
and thus can easily be distinguished from the HSCs.
Pietras et al. described the heterogeneity that exists
among HSCs related to the degree of quiescence. At any
given moment, 90–95 % of HSCs exhibit an “activated”
phenotype and only 5–10 % are “dormant” [41]. In con-
trast, all VSELs are quiescent in nature and as a result
survive the effects of irradiation and chemotherapy.
Ratajczak et al. [31] reported that 1000–1500 cGY total
body irradiation in mice resulted in the loss of HSCs
whereas VSELs survived and 12 % of them incorporated
bromodeoxyuridine (BrdU). Similarly, VSELs survived
and their percentage increased in mouse ovaries [15]
and testis [13] on treatment with busulphan and cyclo-
phosphamide. Recently we have shown that cord-blood
VSELs, which are otherwise quiescent, also enter the cell
cycle in response to 24 h of 5-fluorouracil (5-FU) treat-
ment in vitro [11]. The aim of the present study was to
understand the differential effects of 5-FU on bone mar-
row stem/progenitor cells. 5-FU (150 mg/kg) treatment
depleted cycling cells, thereby creating stress in the
mouse bone marrow and further experiments were
undertaken to study whether recovery of bone marrow
involved only HSCs or also the VSELs.
Recent reports have shown that, along with cytokines
and growth factors, the long-range signaling hormones
also affect HSC activity [42]. The hematopoietic pro-
genitors respond in vitro by proliferation to estrogen
and androgens [43–45]. Administration of estradiol and
an increased level of estrogen as seen during pregnancy
also affect survival, self-renewal, and differentiation of
HSCs [45]. Accumulating evidence suggests that along
with hematopoietic progenitors even VSELs in mouse
BM and human cord blood express receptors for sex
hormones [46, 47]. Mierzejewska et al. [46] reported
that 10-day administration of hormones (follicle-stimu-
lating hormone (FSH), luteinizing hormone, prolactin,
androgen, and estrogen) stimulated proliferation of
VSELs and HSPCs in vivo as evaluated by the uptake of
BrdU. Another study has also recently reported effect-
ive mobilization of VSELs and HSCs into circulation in
15 women being treated with FSH to stimulate ovaries
in an infertility clinic [48]. Our group had initially re-
ported expression of FSH receptor (FSHR) on ovarian
VSELs and OSCs and their modulation by FSH and
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recently observed similar FSHR expression on testicular
VSELs and SSCs and their stimulation by FSH [15, 49–52].
In the present study, different approaches have been
used to further characterize and describe the dynamics
and functional potential in vitro of VSELs and HSCs in
normal and 5-FU-treated adult mouse bone marrow. In
addition, the influence of FSH on the recovery of BM
after 5-FU treatment and whether FSH stimulates self-
renewal, expansion, and/or differentiation of VSELs and
HSCs were studied.
Methods
All experimental protocols used in the present study
were approved by the Institutional Animal Ethics
Committee of NIRRH. Adult Swiss mice 6–8 weeks old
maintained in the institute experimental animal facility
were used for the study. They were housed in a
temperature- and humidity-controlled room on a 12-h
light/12-h darkness cycle with free access to food and
water.
Experimental design
Characterization of VSELs and HSCs in adult mouse BM
Total nucleated cells obtained from mouse BM were stud-
ied for VSELs and HSCs by various methods including
flow cytometry (based on size and marker expression:
VSELs are 3–5 μm and LIN–/CD45–/SCA-1+, whereas
HSCs are ≥6 μm and LIN–/CD45+/SCA-1+), immunolo-
calization to study pluripotent (OCT-4, SSEA-1, SCA-1),
primordial germ cell (STELLA), and proliferation (PCNA)
specific markers, and quantitative RT-PCR studies for
studying pluripotent (Oct-4A, Nanog, Tert), primordial
germ cell (Stella, Fragilis), Sca-1, Oct-4, and proliferation
(Pcna) specific transcripts. Due care was taken to design
Oct-4 primers which were designed from exon 1 to specif-
ically detect Oct-4A and spanning exons 2–4 to detect
total Oct-4 (which majorly includes Oct-4B) as described
earlier [15]. Complete lists of the antibodies and primers
used in the study are provided in Additional file 1: Tables
S1 and S2 respectively.
Effect of 5-FU treatment on mouse BM stem/progenitor cells
Mice were treated with 150 mg/kg body weight of 5-FU
(Biochem, Mumbai, India) via the intraperitoneal route.
The animals were sacrificed 2, 4, and 10 days (D2, D4,
and D10) after the treatment by cervical dislocation and
the harvested BM was processed for characterization
studies as already described along with histological stud-
ies. Besides studying the effect on VSELs and HSCs, flow
cytometry analysis was also performed to study the ef-
fect of 5-FU on proliferation of various subsets of cells
by BrdU uptake and cell-cycle status. The cells that sur-
vived 5-FU treatment were also cultured in Methocult
medium to study their functional potential.
Effect of FSH treatment on stem/progenitor cells in 5-FU-
treated mice
To study the effect of FSH on BM cells in 5-FU-treated
mice, recombinant FSH (5 IU, Gonal F, 10 U; Merck Ser-
ono, Switzerland) was injected subcutaneously 48 h after
animals were treated with 5-FU. BM was harvested after
2 and 5 days of FSH treatment and processed for various
studies as already described. Presence of FSH receptors
on various cell types was also studied by flow cytometry
and immunolocalization studies.
Methods
Isolation of total nucleated cells from mouse BM BM
cells from 6–8-week-old adult Swiss mice were isolated.
Briefly, BM was flushed from tibias and femurs using
DMEM-F12 media (Gibco, Carlsbad, CA, USA) and the
cells were passed through 70 μm filter (Falcon, Corning,
NY, USA). The filtrate was centrifuged at 1000 × g for
10 min and the pellet obtained was resuspended in 1×
RBC lysis buffer (hypotonic ammonium chloride solu-
tion) for 10 min. A population of total nucleated cells
(TNCs) was obtained after lysis of RBCs and washed
twice with DMEM-F12 + 2 % fetal bovine serum (FBS;
Gibco). TNCs obtained by this method were used for
various studies.
Flow cytometry BM cells from normal, 5-FU-treated,
and 5-FU + FSH-treated mice were used for flow cytom-
etry to enumerate Sca-1+/Lin–/CD45– VSELs and Sca-1
+/Lin–/CD45+ HSCs using the gating strategy described
by Kucia et al. [6]. A single-cell suspension was prepared
and stained with FITC-conjugated rat anti-mouse SCA-1
(BD Biosciences, San Jose, CA, USA), PE rat anti-mouse
CD45 (BD Biosciences), and APC mouse Lineage anti-
body cocktail (BD Pharmingen, San Diego, CA, USA)
for 60 min on ice. After washing, the stained cells were
run on FACS Aria (BD Biosciences). At least 105 events
were acquired and results were analyzed by using BD
FACS Diva software (BD Biosciences).
BrdU staining Proliferation events in BM cell popula-
tions were examined by BrdU incorporation in normal
and 5-FU-treated mice by flow cytometry. Briefly, after
5-FU and 5-FU + FSH treatment, the mice were injected
with BrdU (1 mg, intraperitoneal; Sigma-Aldrich, St.
Louis, MO, USA) daily and a final injection of BrdU was
administered 1 h before sacrifice. BM was subsequently
isolated and TNCs were immunostained for CD45, LIN
markers, SCA-1, and BrdU (FITC BrdU Flow Kit; BD
Pharmingen). The manufacturer’s protocol was followed
and the stained cells were run on FACS Aria. The results
obtained were analyzed using FACS Diva software.
Detailed descriptions of the other methods used are
presented in Additional file 1.
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Statistical analysis Arithmetic means and SDs of our
flow cytometry data were calculated, using Graph Pad
prism 6 (GraphPad, San Diego, CA, USA) software.
Data were analyzed using the Student’s t test for un-
paired samples and error bars in graphs represent the
mean ± SEM. Data from bone marrow HSC and VSEL
percentages and numbers are expressed as mean ± SD.
Differences were analyzed using ANOVA (one-way or
multiple comparisons) as appropriate. The significance
level throughout the analyses was chosen to be p ≤ 0.05.
Results
Mouse BM harbors pluripotent VSELs
Earlier reports [6, 53] and our initial immunofluores-
cence studies on cell smears of mice bone marrow con-
firmed the presence of rare, small, spherical cells with
high nucleo-cytoplasmic ratio expressing pluripotent
stem cell markers including nuclear OCT-4A and SOX-
2 and cell-surface SCA-1 and SSEA-1 (Fig. 1a). Interest-
ingly, few larger cells with low nucleo-cytoplasmic ratio
and prominent cytoplasm were also observed which
expressed cytoplasmic OCT-4 (Fig. 1a; Additional file 1:
Figure S1). These cells with cytoplasmic OCT-4 were
present in more numbers and were possibly the HSCs.
Based on these initial results, the BM cells were investi-
gated further by flow cytometry (Fig. 1b) using the
protocol and unique gating strategy reported by Kucia et
al. [6]. Small cells (2–8 μm) were gated and analyzed for
expression of Lineage (LIN) markers and pluripotent
stem cell marker (SCA-1). Next, the LIN–/SCA-1+ cells
were gated and analyzed for the expression of
hematopoietic marker CD45. The LIN– and CD45–
non-hematopoietic cells expressing pluripotent marker
SCA-1 were the VSELs (LIN–/CD45–/SCA-1+), while
the LIN–CD45+ hematopoietic cells with SCA-1
expression were the HSCs (LIN–/CD45+/SCA-1+). As
shown in Fig. 1b, the percentage of VSELs (0.022 ±
0.002 %) was almost 3-fold lower than the HSCs
(0.081 ± 0.004 %) (n = 10). A similar strategy was used
to determine the percentage of small cells expressing
OCT-4A and SSEA-1 and it was observed that the per-
centage of LIN–/CD45– cells co-expressing these markers
was almost similar to SCA-1+ VSELs (Additional file 1:
Table S3). This co-expression of markers in the small cells
suggested that SCA-1+ VSELs also express OCT-4A and
SSEA-1. Dual immunostaining of the bone marrow
smears confirmed that cells co-expressed SCA-1 with
OCT-4A and SCA-1 with SSEA-1 (Fig. 1c).
From confocal microscopy and flow cytometry studies
of intact mouse BM, it was thus confirmed that in
addition to the abundant LIN–/CD45–/SCA-1+ HSCs
with cytoplasmic OCT-4, mouse bone marrow contained
very-small-sized LIN–/CD45–/SCA-1+ VSELs expressing
pluripotent markers (nuclear OCT-4 and cell-surface
SSEA-1).
5-FU treatment spares primitive stem/progenitor cells
The effect of 5-FU was studied on mouse BM cellularity
by examining the histological sections of decalcified femur
post treatment on D2, D4, and D10 along with untreated
controls. 5-FU treatment caused an apparent reduction in
cell numbers (Fig. 2b) compared with control (Fig. 2a),
with the lowest bone marrow cellularity observed on D4
(Fig. 2c); however by D10, BM sections showed similar
histoarchitecture to that of the control sections, confirm-
ing endogenous regeneration (Fig. 2d). Also, 5-FU treat-
ment resulted in a marked influx of erythrocytes in the
bone marrow on D4 (Fig. 2c). Histological observations
were further confirmed by BM total cell count taken on
the same days. As expected, the cell count steadily de-
creased by 3-fold on D2 and by 7-fold on D4 (p < 0.001)
compared with the control (Fig. 3a). The cell count on D4
(3.04 ± 0.79 × 106) was at least 2-fold lower (p < 0.001)
than on D2 (7.65 ± 0.74 × 106). On D10 post treatment,
the cell numbers (10.42 ± 2.3 × 106) were increased, sug-
gestive of endogenous bone marrow regeneration.
We further studied the effect of 5-FU treatment on cell
fractions enriched for VSELs (LIN–/CD45–), HSCs (LIN–/
CD45+), and mature hematopoietic cells comprising mye-
loid and lymphoid progenitors (LIN+/CD45+) by flow
cytometry. The percentage of these cells was calculated
pre and post 5-FU treatment (Fig. 3b). A 1.3-fold decrease
in the LIN+/CD45+ cells was observed compared with
control on D4 post treatment (Fig. 3b). However there
was an increase in the percentages of both LIN–/CD45–
(p < 0.01) and LIN–/CD45+ (p < 0.001) compared with
control on D4 post treatment (Fig. 3b). The results con-
firmed that 5-FU affects the cycling myeloid and
lymphoid compartments while sparing the primitive
stem/progenitor populations that are either slow cyc-
ling or quiescent. By D10 an increase in the percentage
of LIN+/CD45+ cells was observed with endogenous
bone marrow regeneration (Fig. 3b).
Detailed studies were undertaken on the cells that
survived in mouse BM on D4 post 5-FU treatment. The
quantitative RT-PCR analysis of these cells showed in-
creased expression of pluripotent (Oct-4A, Oct-4, Sca-1
Nanog, and Tert), primordial germ cell (Stella, Fragilis),
and proliferation (Pcna) specific transcripts (Fig. 3c).
Hematoxylin and eosin (H & E)-stained sections of 5-
FU-treated femur on D4 showed the presence of cells
with small size, spherical shape, high nucleo-cytoplasmic
ratio, and darkly stained nuclei in close proximity of the
bone endosteal region (Fig. 3d) These cells expressed nu-
clear OCT-4 and were observed either singly or in small
clusters close to the endosteal region (Fig. 3f). Confocal
microscopy studies also demonstrated the expression of
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SSEA-1, SCA-1 (Fig. 3g), and OCT-4 (Fig. 3h) positive
cells in 5-FU-treated smears and cryosections respectively.
From these results it is evident that within 48 h of 5-
FU treatment all of the cycling cells in the bone marrow
were depleted, and endogenous recolonization of the
bone marrow occurred by D10. Characterization studies
confirmed that VSELs expressing nuclear OCT4-A and
SCA-1 survived the effects of 5-FU treatment.
Fig. 1 Pluripotent very small embryonic-like stem cells (VSELs) in adult mouse bone marrow. a Expression of pluripotent stem cell makers including
nuclear OCT-4 (red) and SOX-2 (red) and cell surface SSEA-1 (green) and SCA-1 (green) were detected on small-sized cells in bone marrow smears. Also
note presence of cytoplasmic OCT-4 in slightly bigger cells. These cells were more abundant and please refer to Additional file 1: Figure S1 to see
additional images of cytoplasmic OCT-4-expressing cells. Scale bar = 20 μm. b Flow cytometry analysis of VSELs and HSCs in bone marrow. Cells of size
2–8 μm were gated using size calibration beads as reference, followed by sequential selection of LIN–/SCA-1+ cells. This population was evaluated for
expression of CD45. The LIN–/SCA-1+/CD45– cells were VSELs, while LIN–/SCA+/CD45+ cells were HSCs. The average percentage of VSELs and HSCs with
SD from 10 experiments is reported. Representative image is shown. c Dual immunofluorescence was performed using anti-SSEA1 antibody (green)
with nuclear OCT-4 (red, upper) and SCA-1 (red, lower). Cells co-expressing nuclear OCT-4 and SSEA-1 and SSEA-1 and SCA-1 were observed.
Scale bar = 20 μm. In all images, nuclei are counterstained with DAPI. HSC Hematopoietic stem cell, OCT-4 octamer binding transforming factor-4,
SSEA-1 stage-specific embryonic antigen-1, Sca-1 stem cell antigen-1, Sox 2 sex-determining region (box 2), DAPI 4′,6-diamidino-2-phenylindole
(Color figure online)
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VSELs survive and proliferate in response to 5-FU
treatment
Flow cytometry analysis confirmed survival and an in-
crease in the numbers of LIN–/CD45–/SCA-1+ VSELs
and LIN–/CD45+/SCA-1+ HSCs after 5-FU treatment.
The VSELs were resistant to 5-FU and the percentage
of VSELs increased on D2 after treatment (Fig. 4a).
However, to confirm that the increase in percentage
was not a result of decreased bone marrow cellularity,
absolute numbers were calculated (Table 1). These
data showed that the VSELs remained constant after
treatment whereas more than 50 % of HSCs were
destroyed by 5-FU.
The percentage and absolute numbers of VSELs and
HSCs were also calculated on D4 and D10 post treat-
ment (Fig. 4a, Table 1). There was an increase in per-
centage and absolute numbers of VSELs and HSCs on
D4 (VSELs 0.201 ± 0.03 %, HSCs 0.423 ± 0.07 %;
Table 1). With the increase in BM cellularity by D10,
VSELs reduced slightly but HSC numbers were still
high (Table 1). Also the percentage of HSCs was always
higher compared with VSELs on all of the days. The
expansion in VSELs and HSCs on D4 suggested that
these quiescent cells were activated and entered the cell
cycle in response to the stress induced by 5-FU. An
increase in numbers of both VSELs and HSCs was
observed with higher HSC numbers compared with the
VSELs.
The increase in VSEL and HSC number post treat-
ment (Table 1) suggested that they may be proliferating
due to the “regenerative pressure” to meet the increased
demand of progenitors. This proliferative status of the
bone marrow stem/progenitor cells was studied by
evaluating the percentage of cycling cells post 5-FU
treatment. The percentage of S-phase cells decreased on
D2 of 5-FU treatment, further confirming that 5-FU
destroyed cycling cells (Fig. 4b). By D4, the percentage
of cells in S-phase increased and was associated with a
decrease in the G0/G1 cell percentage. This increase
suggests self-renewal (activation/involvement) of quies-
cent cells to restore hematopoiesis by D10.
An in vivo BrdU incorporation assay was then carried
out to examine whether both the LIN–/CD45+ (enriched in
HSCs) and LIN–/CD45– (enriched in VSELs) populations
Fig. 2 Effect of 5-FU on bone marrow cellularity. Hematoxylin and eosin-stained sections of decalcified femur (a) and affected histology on D2,
D4, and D10 (b–d) after 5-FU treatment. Gradual decrease in bone marrow cells is observed on D2 (b) and D4 (c) with lowest cellularity on D4 (c)
compared with control (a). By D10, endogenous recovery of hematopoiesis is seen (d). Note an influx of RBCs on D2 and D4. Scale bar = 20 μm. All
images are taken on the Nikon 90i microscope. D2-5-FU, D4-5-FU, D10-5-FU days post 5-fluorouracil treatment
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Fig. 3 (See legend on next page.)
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proliferated in response to 5-FU treatment. There was
a significant increase in the BrdU uptake by both these
cell types (p < 0.001) on D4 compared with untreated
control, confirming their proliferation (Fig. 4c). BM
cryosections on D4 showed the presence of VSELs
which co-expressed nuclear OCT-4 and PCNA near
the endosteal region of the BM (Fig. 5a). Together, the
uptake of BrdU by non-hematopoietic cells and the
expression proliferation marker PCNA by the pluripo-
tent OCT4-expressing cells confirms that VSELs
underwent self-renewal and thus contributed to re-
storing hematopoiesis by D10. We further examined
the functional potential of cells that survived 5-FU
treatment in vitro using a colony-forming unit (CFU)
assay. Cells that survived 5-FU responded to the cyto-
kines in the Methocult media and developed 20–25
small and large colonies (Fig. 5b–e).
5-FU treatment mirrored a state of stress in the bone
marrow with the need to form blood cells to recolonize
the marrow. Several groups have already shown that
VSELs remain dormant most of the time, entering the
cell cycle only under stress and injury [13, 15, 24–30].
Because of 5-FU-induced stress in the present study,
VSELs underwent a short burst of proliferation and
then by D10 their numbers became equivalent to the
control; in contrast, the HSC numbers initially de-
creased dramatically, but after D4 showed high prolifer-
ative potential. This expansion in HSCs with a small
but significant increase in VSELs suggests that VSELs
may be proliferating to meet increased demand of their
immediate progenitor HSCs. These results are in agree-
ment with the stem cell/progenitor concept wherein
the most primitive stem cells undergo rare asymmetric di-
visions to self-renew and give rise to the progenitors
which in turn divide rapidly and undergo clonal expansion
followed by differentiation to maintain tissue homeostasis.
FSH enhances hematopoietic recovery from VSELs
To outline the effect of FSH on stem/progenitor cells in
the mouse BM, initially the expression of FSHR on the
bone marrow cells was studied. Immunofluorescence
studies on BM cells that survived 5-FU treatment on D4
showed cell surface expression of FSHR on cells of two
distinct sizes (Fig. 6a, b; Additional file 1: Figure S3).
Co-expression of SCA-1 and FSHR was also observed,
confirming that indeed stem/progenitors express FSHR
(Fig. 6c). In addition to FSHR, cells that survived 5-FU
treatment also expressed the primordial germ cell (PGC)
marker STELLA (Additional file 1: Figure S2) and
showed increase in PGC transcripts (Fig. 3c). Immuno-
phenotyping results (Additional file 1: Table S4, Figure
S3) showed that only 6 % of LIN–/CD45– VSELs and
10 % of LIN–/CD45+ HSCs expressed FSHR.
We next determined whether the cells surviving in
the BM after 5-FU treatment responded to FSH.
Recombinant human FSH (5 IU, subcutaneous) was ad-
ministered 48 h post 5-FU treatment (5-FU + FSH
group) and its effects were examined 2 days later
(Fig. 6d) and compared with 5-FU-treated mice without
FSH (5-FU – FSH group). Analysis of the cell count
(data not shown) and H & E stained sections of bone
marrow from both the groups showed a slight increase
in bone marrow cellularity in response to FSH treatment.
Moreover, on D7 post 5-FU treatment the BM architec-
ture of the 5-FU + FSH group showed restoration of bone
marrow hematopoiesis (Fig. 6e). This suggested that FSH
enhanced the process of hematopoietic recovery by 72 h
in the 5-FU + FSH group because complete recovery was
noted in the 5-FU – FSH group only by D10.
The stem/progenitor cells in bone marrow (which
survived 5-FU) also responded to FSH treatment. There
was a small increase in the absolute numbers of VSELs
(5890 untreated vs 6455 FSH treated) and a 1.25-fold
(See figure on previous page.)
Fig. 3 Mature and actively dividing cells in BM are affected by 5-FU whereas primitive and relatively quiescent stem cells are spared. a The total
BM nucleated cells isolated from two femurs and two tibias of the mice were counted on D2, D4, and D10 after 5-FU treatment and compared
with control. Similar to histological data (Fig. 2); the cell count decreased up to D4 (7-fold) and is increased on D10 (n = 10, ***p≤ 0.001). b The
percentage of various bone marrow subtypes based on Lin and CD45 expression were evaluated on D4 and D10 after 5-FU treatment. Note that
while the percentage of Lin+/CD45+ subtypes decreased on D4, its percentage increased with hematopoietic recovery. Percentage of Lin–/CD45– (enriched
in VSELs) increased on D4 and slightly reduced by D10. The Lin–/CD45+ (enriched in HSCs) percentage also increased by D4, and remained high on D10
(n = 10, ***p≤ 0.001). c Upregulation in the pluripotent, primordial germ cell and proliferation specific transcripts is observed in BM cells that survive
5-FU on D4. The upregulation of these markers confirms the presence and involvement of primitive stem cells in regeneration. The transcript levels on
D4 are shown compared with control (n = 6, *p≤ 0.05; **p≤ 0.01). Bars in a, b represent average ± SD and in c average ± SEM. d–h Characterization of
cells on D4 that survived 5-FU treatment. d H & E staining shows VSELs which are spherical in shape and small in size with high nucleo-
cytoplasmic ratio located near the endosteal region. Inset (e) shows cells at higher magnification. f Nuclear OCT-4+ VSELs are clearly visualized in bone
marrow sections cells in clusters (*) or singly (arrow) along the endosteal region; these cells also express (g) cell-surface SSEA-1and (h) nuclear
SCA-1. Presence of nuclear OCT-4, SSEA-1, and SCA-1 confirms that VSELs survive 5-FU treatment. Nuclei are counterstained with DAPI. Scale
bar = 20 μm for H & E and immunohistochemistry images, scale bar = 10 μm for immunofluorescence images. Day 2-FU, Day 4-FU, Day 10-FU days post
5-FU treatment, BM bone marrow, 5-FU 5-fluorouracil, H & E Hematoxylin and Eosin, OCT-4 octamer binding transforming factor-4, SSEA-1 stage-specific
embryonic antigen-1, SCA-1, stem cell antigen-1, DAPI 4′,6-diamidino-2-phenylindole
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rise in HSC numbers (p < 0.001) after FSH treatment
(15,309 FSH treated vs 12,295 untreated) compared
with untreated controls (Fig. 6f ). To confirm that FSH
indeed brought about proliferation of surviving BM
stem/progenitor cells and did not just aid in their sur-
vival, BrdU incorporation was studied in the LIN–/
CD45– and LIN–/CD45+ cells. Similar to our findings
in the VSEL and HSC numbers, there was marginal in-
crease (7693 untreated vs 8425 FSH treated) in LIN–/
CD45–/BrdU+ cells that are enriched in VSELs along
with a remarkable increase (23,699 untreated vs 33,507
FSH treated; 1.41-fold, p < 0.01) even in the LIN–/CD45+
cells (enriched in HSCs, Fig. 6g). The huge expansion in
HSCs with minimal increase in VSEL numbers advocates
that FSH influences both self-renewal of VSELs and rapid
proliferation of progenitors (HSCs) which will then differ-
entiate further to restore hematopoiesis.
The quantitative RT-PCR data of the 5-FU + FSH
group showed that treatment also had an effect on the
pluripotent stem cell marker expression (Fig. 6h). The
transcripts for Oct-4A, Nanog, Sca-1, and Pcna were up-
regulated compared to the group without FSH, with an
almost 21-fold increase (p < 0.05) in the expression of
Oct-4. FSH treatment also resulted in the upregulation
of the transcripts specific for primordial germ cell spe-
cific transcripts including a 2-fold increase in Fragilis
and a 12-fold increase (p < 0.05) in Stella. These results
add another level of confirmation to the stimulatory
effect of FSH on VSELs and HSCs in the bone marrow
post 5-FU.
To conclude, the results of this section show that a
fraction of stem/progenitors which survive 5-FU treat-
ment express FSHR and are stimulated by FSH to
enhance recolonization by 72 h. A several-fold
increase in transcripts specific for Oct-4 (reflecting
HSCs) and a marginal increase in Oct-4A (reflecting
VSELs) confirmed a larger response of HSCs com-
pared with VSELs which was noted also at the protein
level. Further, a 12-fold increase in transcripts specific
for Stella vs 2-fold increase in Fragilis suggests that
only a fraction of perhaps more committed VSELs ex-
press FSHR and respond to FSH. These observations
require further investigation.
Fig. 4 Mouse BM stem/progenitor cells survive and proliferate in
response to 5-FU treatment. a Flow cytometry analysis of LIN–/CD45–
VSELs and LIN–/CD45+ HSCs showed an increase in percentage post
treatment compared with control. Compared with D2, a significant
increase was observed on D4. On D10 the percentage of both these
cells is reduced (N = 12, ***p≤ 0.001). b Propidium iodide-based cell
cycle analysis of BM cells carried out on D2, D4, and D10 after 5-FU
compared with the control showed a decrease in S-phase cells on D2
and an increase in the G0/G1 cell percentage. By D4 the percentage of
S-phase cells increased and continued until D10. The increase in
S-phase cells suggests proliferation of cells in response to 5-FU
treatment (N = 6, ***p ≤ 0.001). c Proliferation of VSELs (LIN–/
CD45–) and HSCs (Lin–/CD45+) was confirmed by an increase in
percentage of BrdU-positive cells on D4 compared with control
(N = 5, **p ≤ 0.01,***p ≤ 0.001). In (a-c) Bars represent average ±
SD. Day 2-FU, Day 4-FU, Day 10-FU days post 5-fluorouracil treatment,
BM bone marrow, VSEL very small embryonic-like stem cell, HSC
hematopoietic stem cell, BrdU bromodeoxyuridine
Table 1 Absolute numbers of VSELs and HSCs in adult mouse
bone marrow
Treatment group VSELs (× 103) HSCs (× 103)
Control (no treatment) 3.77 ± 1.01 14.07 ± 3.60
Day 2 post 5-FU 3.49 ± 0.45 8.63 ± 0.70
Day 4 post 5-FU 5.89 ± 0.82 12.29 ± 1.59
Day 10 post 5-FU 4.22 ± 0.80 23.73 ± 3.25
VSEL very small embryonic-like stem cell, HSC hematopoietic stem cell,
5-FU 5-fluorouracil
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Discussion
VSELs were identified and characterized in various adult
organs in mice in 2006 [6] and since then several reports
have highlighted their presence in human tissues as well,
and even their translational potential is beginning to
emerge [54–61]. Results of the present study confirm
the presence of LIN–/CD45–/SCA-1+ VSELs (0.022 ±
0.002 %) along with LIN–/CD45+/SCA-1+ HSCs (0.081
± 0.004 %) in mouse bone marrow. VSELs were small in
size and co-expressed nuclear OCT-4, SCA-1, and
SSEA-1 and pluripotent (Oct-4A, Sca-1, Nanog, Tert) as
well as primordial germ cell (Stella, Fragilis) specific
transcripts. HSCs were slightly bigger in size, expressed
cytoplasmic OCT-4, and were present in relatively
greater numbers. VSELs were found to express both
pluripotent and primordial germ cell specific markers
since it is postulated that they share a developmental
link with primordial germ cells [23]. These results are in
agreement with our earlier report on human cord blood
[11] and with other studies that have reported high expres-
sion of primordial germ cell specific transcripts Vasa,
Blimp1, Stella, Prdm14, Nanos3, and Fragilis in VSELs [62].
A precaution taken in the present study for detecting
VSELs along with the HSCs was the use of a speed of
1000 × g to spin-down cells at various steps during pro-
cessing since VSELs are invariably lost during processing
at lower speeds. The inability to detect VSELs in mouse
BM in a recent study [63] is most probably because a
low speed of 400 xg was used while processing, which
probably resulted in loss of VSELs in the supernatant.
Similarly VSELs have been invariably and unknowingly
discarded along with the RBCs [10] on density gradient
centrifugation of cord blood samples. VSELs are en-
dogenous pluripotent stem cells and a possible, novel
candidate for regenerative medicine in addition to hu-
man embryonic and induced pluripotent stem cells.
Fig. 5 Proliferation of nuclear OCT-4+ VSELs. a Dual immunofluorescence on cryosections of D4 femur detected the presence of nuclear OCT-4+
cells co-expressing proliferation marker PCNA. Nuclear OCT-4/PCNA co-expressing VSELs were observed close to the endosteal region. The nuclei
were counterstained with DAPI. Scale bar = 100 μm. Inset: magnified image of cluster of OCT-4/PCNA coexpressing cells. Scale bar = 10 μm. b, c
Results of the CFU assay: small and large hematopoietic colonies of type CFU-GM or CFU-GEMM were observed on culture of cells that survived
5-FU on D4 in Methocult media. d GFP+ cell clusters observed after 10 days of culture of 5-FU-treated GFP cells in Methocult media. e Typical
cobblestone formation representative of hematopoietic colonies seen in 5-FU-treated cell culture. f Representative image of colonies observed in
CFU assay at 20× magnification, colony formed is of the type CFU-GEMM. OCT-4 octamer binding transforming factor-4, PCNA proliferating cell nuclear
antigen, DAPI 4′,6-diamidino-2-phenylindole, CFU-GM colony-forming unit granulocytes/macrophage, CFU-GEMM colony-forming unit-granulocyte,
erythroid, macrophage, megakaryocyte
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Fig. 6 (See legend on next page.)
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One of the main objectives of the present study was to
examine the effects of 5-FU on VSELs and to investigate
whether VSELs contribute to hematopoiesis in vivo.
Under steady-state conditions, VSELs remain quiescent
but in response to tissue injury or stress they are acti-
vated and mobilize to the affected area [24–30]. A con-
dition of bone marrow stress was thus used in the
present study to understand the role of VSELs in bone
marrow regeneration. 5-FU, a chemotherapeutic agent,
rapidly depletes the cycling myeloid and lymphoid pro-
genitors [64–67]. This creates a dearth of progenitors in
the bone marrow and cytotoxic stress is established.
Additionally, treatment with 5-FU spares the slow cyc-
ling and dormant cells, thereby resulting in bone mar-
row enriched in primitive stem cells [68–71]. Even in
the present study, as expected 5-FU caused 7-fold deple-
tion in bone marrow cellularity by D4 and spontaneous
endogenous recovery of the bone marrow occurred by
D10, which established a basal timeline for the later
experiments.
The kinetics of VSELs and HSCs was studied further
within this period of 2–10 days post treatment. VSELs,
being the most primitive cells in the bone marrow and
quiescent under normal conditions, were resistant to the
effects of 5-FU confirmed by no change in their num-
bers on D2 (3.49 ± 0.45 × 103) compared with untreated
control (3.77 ± 1.01 × 103). On the other hand, more
than 50 % of HSCs were depleted in response to 5-FU
(8.63 ± 0.70 × 103) on D2 compared with untreated con-
trol (14.07 ± 3.60 × 103) in agreement with earlier reports
[67, 69, 72]. The bias in the effect of 5-FU on HSCs was
possibly due to the presence of two separate sub-
populations within the HSCs, comprising of the quies-
cent cells that survive 5-FU cytotoxicity and the actively
dividing cells which get depleted. These two sub-
populations have been described as long- and short-term
repopulating subsets of HSCs which show varying de-
gree of radioprotection [73].
The increase in numbers of both VSELs and HSCs in
response to 5-FU confirmed at both protein and mRNA
levels and by BrdU and cell cycle analysis in the present
study suggests that the stem/progenitor cells get acti-
vated in response to stress, and both proliferate but the
extent of proliferation of HSCs is much higher com-
pared with VSELs. This compensatory expansion of
stem/progenitors initiates regeneration of chemoablated
BM. Our results are in agreement with earlier reports by
Ratajczak et al. [31], who reported BrdU incorporation
in 12 % of the VSELs post irradiation in mouse bone
marrow. Similarly, Baldrige et al. [74] also reported acti-
vation of both intermediate blood progenitors and
primitive long term-HSCs (LT-HSCs) after chronic bac-
terial infection. Conclusive evidence that VSELs survive
and proliferate in BM after 5-FU treatment is provided
by us for the first time in the literature by dual immuno-
fluorescence studies on BM sections. Nuclear OCT-4A
and PCNA-expressing VSELs are clearly evident on D4
along the endosteal region of the BM which is considered
to be the niche for stem cells [75, 76]. The niche maintains
stem cells pool in vivo and regulates the hematopoietic re-
covery after myelo-suppression [77–79]. The regenerative
ability of cells that survive chemoablation in BM was also
confirmed by CFU assay in vitro that resulted in colony
formation in Methocult media, thus implying that surviv-
ing 5-FU cells are functional and can form mature blood
lineages to recolonize the BM.
Furthermore, we report two distinct sizes of cells (pos-
sibly VSELs and HSCs) expressing FSHR in ablated BM.
Similar expression of FSHR on stem/progenitors has been
reported in mouse BM and cord blood [46, 47] and on
ovarian and testicular stem/progenitors cells by our group
[49–52]. However further studies are required to examine
this in a more quantitative manner because we found only
6 % of LIN–/CD45– VSELs and 10 % of LIN–/CD45+
HSCs expressing FSHR by immunophenotyping studies.
Our group has earlier shown that FSH treatment stimu-
lates ovarian and testicular VSELs to self-renew in che-
moablated gonads and also stimulates clonal expansion of
progenitors [15, 50, 52]. Recently, Zbucka-Kretowska et al.
[48] reported that FSH mobilized BM stem/progenitor
(See figure on previous page.)
Fig. 6 Hematopoiesis recovery is augmented after FSH treatment. a, b Cell surface expression of FSHR (green) on both small VSELs (top panel)
and slightly bigger HSCs (bottom panel) which survive 5-FU treatment in mouse BM on D4. c Co-expression of SCA-1 (red) and FSHR (green) on
the same cells. The nuclei are counterstained with DAPI. Scale bar = 20 μm. d, e H & E sections on D4 showed increased BM cellularity after FSH
treatment on D4 (d) compared with FSH minus control. e In 5-FU + FSH-treated sections, the endogenous bone marrow regeneration was almost
complete by D7 after 5-FU treatment compared with untreated controls. f Flow cytometry data showed an increase in number of VSELs and HSCs
on FSH treatment. g BrdU uptake also increased on FSH treatment slightly in the primitive Lin–/CD45– (enriched in VSELs) while a significant
increase (p < 0.001) was seen in Lin–/CD45+ (HSC-enriched) cells. h Upregulation of transcripts specific for pluripotent, primordial germ cells, and
proliferation markers on FSH treatment compared with untreated controls. Significant increase in Oct-4 and Stella transcripts was observed. Please
note that Oct-4 transcripts (which reflect HSCs) were more than Oct-4A (which reflects VSELs). Bars in f, g represent average ± SD and in h average ±
SEM. Representative of five experiments in f, g and in h data obtained from three experiments. *p≤ 0.05. ***p≤ 0.001. D4-5-FU, D7-5-FU days post 5-FU
treatment, FSH follicle-stimulating hormone, BM bone marrow, 5-FU 5-fluorouracil, H & E hematoxylin and eosin, VSEL very small embryonic-like stem
cell, FSHR follicle stimulating hormone receptor, SCA-1 stem cell antigen-1, HSC hematopoietic stem cell, OCT-4 octamer binding transforming factor-4,
BrdU bromodeoxyuridine (Color figure online)
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cells into circulation but not endothelial progenitor cells
in 15 female patients on FSH therapy for ovarian stimula-
tion in an infertility clinic. The augmented hematopoietic
recovery on D7 in response to FSH treatment noted in the
present study after compared with D10 in untreated mice
provides further evidence that indeed FSH influences
stem/progenitor cells in BM. The enhanced recovery on
FSH treatment was found to be accompanied with a mar-
ginal increase in the number of VSELs and a dramatic in-
crease in HSCs and differentiated cells.
True stem cells are expected to divide asymmetrically
(ACD) and give rise to two distinct cell types, whereas the
progenitors that arise by ACD of stem cells undergo rapid
symmetric divisions (SCD) and differentiation to maintain
tissue homeostasis. Although the HSCs are the best inves-
tigated human somatic stem cells, which cells undergo
ACD is still not clearly understood [80]. Emerging evi-
dence suggests that (1) VSELs are the most primitive
small-sized stem cells in the BM in addition to actively
dividing, larger sized HSCs, (2) VSELs give rise to HSCs
based on in-vitro studies [31, 32] and the OCT-4 expres-
sion pattern shown in the present study wherein VSELs
express nuclear OCT-4A and HSCs express cytoplasmic
OCT-4, and (3) both VSELs and HSCs are stimulated and
take part in regeneration of BM under stress conditions
shown in the present study and also reported earlier
[13, 15, 31]. Based on this we suggest that VSELs may
correspond to the LT-HSCs. A recent report of a simi-
lar imprinting pattern of erasure at the IgF2-H19 locus
to maintain quiescence in LT-HSCs [81] and VSELs
[82] provides further evidence of a link between these
cells. VSELs are probably the true stem cells in the
hematopoietic system that undergo ACD to self-renew
and give rise to HSCs which are actively dividing pro-
genitors that further differentiate into various blood cell
types. This was recently discussed in detail in various
adult organs [83].
Certain changes in the niche may push the stem cells
to undergo uncontrolled proliferation resulting in can-
cer/leukemia. If this was true the stem cells and cancer
cells should share similar markers. Recently Zhao et al.
[84] found a significantly increased nuclear OCT-4A
expression in patients with acute leukemia. This obser-
vation combined with current understanding that VSELs
are the most primitive cells expressing nuclear OCT-4A,
it can be hypothesized that in the case of leukemia,
changes in the niche push the relatively quiescent VSELs
to undergo uncontrolled proliferation. This link between
VSELs and HSCs and leukemia stem cells warrants fur-
ther investigation.
Conclusions
To summarize, bone marrow houses pluripotent VSELs
which give rise to the HSCs. VSELs and a subset of HSCs
survive 5-FU-induced stress and are activated to recolonize
the chemoablated BM. VSELs/HSCs also express FSHR
and thus FSH treatment expedites BM regeneration by al-
most 72 h. This opens up a newer avenue for use of FSH
in the clinical setting while treating bone marrow failure
and irradiation patients. Our results provide better under-
standing towards the stem/progenitor cell hierarchy in the
hematopoietic system. Studying the factors released by the
niche cells which activate stem/progenitor cells to regener-
ate BM cells under stress conditions and also which result
in uncontrolled proliferation and expansion of Oct-4A+
VSELs in leukemia patients is warranted.
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